Editorial Board ::: Current Immunology Reviews

ISSN: 1875-631X (Online)
ISSN: 1573-3955 (Print)


Volume 13, 2 Issues, 2017


Download PDF Flyer




Current Immunology Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Cecil Czerkinsky
Institut de Pharmacologie Moleculaire et Cellulaire
UMR 7275 CNRS-INSERM-UNISA
660 Route des Lucioles
Valbonne, 06560
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Cecil Czerkinsky (Biography
Cecil Czerkinsky

Dr. Czerkinsky is currently Research Director at the Institute of Molecular and Cellular Pharmacology, a research organization spearheaded by the French National Research Council (CNRS), the National Institute of Health and Medical Research (INSERM) and the University of Nice at Sophia Antipolis (France). He previously served as Deputy Director General and Head of R&D at the International Vaccine Institute (Seoul, South Korea) and as Professor at Seoul National University, Korea University, and Göteborg University (Sweden). He has authored more than 180 scientific publications and is an inventor of more than 20 patents in the field of immunology and vaccine science.

)

Institut de Pharmacologie Moleculaire et Cellulaire
UMR 7275 CNRS-INSERM-UNISA
660 Route des Lucioles
Valbonne, 06560
France



Co-Editor:

S. Gupta
University of California
Irvine, CA
USA


Associate Editors:

M. Emoto (Biography
M. Emoto

He is now a professor of Gunma University Graduate School of Health Sciences in Japan. He got the professorship in 1993 and his main research theme is NKT cells. Before coming back to Japan, he has worked at Max Planck Institute for Infection Biology in Berlin, Germany as a higher ranking senior scientist approx. 10 years with Prof. Dr. Stefan H. E. Kaufman, who was a president of International Union of Immunological societies, and published many articles in prestigious journals with high impact factor. Although he is an associate editor in this journal, he also serves as editors in more than 40 journals including Editor-in-Chief. He has concentrated on identification of new natural ligand(s) for invariant NKT cells and nowadays he has succeeded to determine their chemical structures. Thus, he is a leading scientist in the field of NKT cells.

)

Gunma University School of Health Sciences
Gunma
Japan

C.A. Guzman (Biography
C.A. Guzman

Prof. Guzmán graduated as Doctor of Medicine and Surgery (MD) and Doctorate of Research in Microbiological Sciences (PhD) from the University of Genoa, Italy. He is currently an APL-Professor at the Medical School of Hannover, Germany and Head of the Department of Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research, Braunschweig, Germany. He has been working in the field of Vaccinology since 1989 with the specific goal of establishing tools and strategies to prevent infectious diseases. His work has been instrumental for the development of new adjuvants, antigen delivery systems and preclinical validation models, leading to more than 200 articles and several international patents.

)

Helmholtz Centre for Infection Research
Braunschweig
Germany


Regional Editors:

E. Rajnavolgyi
University of Debrecen (UD)
Debrecen
Hungary

H. Umehara (Biography
H. Umehara

Dr. Umehara is Director of North County Center for RA and Autoimmune Diseases (NCC-RA2ID), Hayashi Hospital. He is a Rheumatologist with wide knowledge of Clinical and Basic Immunology. Previously, Dr. Umehara was professor and chairman, Kanazawa Medical University, and served as the Japanese director of Sjögren’s International Collaborative Clinical Alliance (SICCA) during 2006 to 2014. He was also a chairman of All Japan IgG4-RD team by Health, Labor and Welfare, Japan (2011-2013) and published comprehensive diagnostic criteria for IgG4-RD, 2011.

)

Nagahama City Hospital
Oinuicho Nagahama
Shiga
Japan


Editorial Board Members:

E.E. Adderson (Biography
E.E. Adderson

Dr. Adderson graduated from the University of Alberta School of Medicine and trained in Pediatrics and Pediatric Infectious Diseases at Dalhousie University and Washington University School of Medicine. Her research interests are in the epidemiology of infections in immunocompromised children and vaccine development.

)

St. Indes Childers Research. Hospital
Memphis, TN
USA

S Akira
Osaka University
Osaka
Japan

J Beck
University of Michigan Medical School
Ann Arbor, MI
USA

Robert K. Bright (Biography
Robert K. Bright

Dr. Bright is a Professor of Immunology in the School of Medicine at Texas Tech University Health Sciences Center. He earned a PhD from the University of Texas Health Sciences Center in 1994, and was awarded an Intramural Research Training Award Fellowship to study tumor immunology in the Surgery Branch of the National Cancer Institute, NIH. He has more than 20 years of experience in research focusing on tumor immunity, has been funded by the NIH, the American Cancer Society and the DOD CDMRP, and has over 90 publications in the area of tumor immunology and tumor vaccines.

)

Texas Tech University Health Sciences Center
Lubbock
United States

G. Casorati
DIBIT, San Raffaele Scientific Institute
Milano
Italy

Y. Choi
University of Pennsylvania School of Medicine
Philadelphia, PA
USA

D. Conrad
Virginia Commonwealth University
Richmond, VA
USA

E. Denkers
Cornell University
Ithaca, NY
USA

R. Dziarski
Indiana University School of Medicine
Gary, IN
USA

J Frelinger (Biography
J Frelinger

Jeffrey A. Frelinger received his PhD from Caltech working with Ray Owen, He postdoced at the University of Michigan where he and Chella David and Donald Shreffler described MHC class II. He founded his own lab at the University of Southern California, he focused on the function MHC encoded molecules, and began a serious entre into the molecular genetics of the MHC. He was recruited to UNC in1983. He served as Head of the Cancer Immunology Program in the Lineberger Cancer Center, and then as Kenan Professor and Chair of the Department of Microbiology and Immunology. He moved to the University of Arizona in 2010 where he serves as Professor of Immunobiology. He received an NIH MERIT award and served as President of the American Association of Immunologists.

)

University of North Carolina
Chapel Hill, NC
USA

M Goldman
Université Libre de Bruxelles
Brusselscity
Belgium

Yajun Guo
SMMU Cancer Institute
Shanghai
China

C. Hogaboam
University of Michigan Medical School
Ann Arbor, MI
USA

N. Isakov (Biography
N. Isakov

Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).

)

Ben Gurion University of the Negev
Beer Sheva
Israel

S. Kaufmann
Max-Planck-Institute for Infection Biology
Berlin
Germany

D. Klinman (Biography
D. Klinman

Dr. Klinman is a Senior Investigator at the National Cancer Institute. He received his MD/PhD from the University of Pennsylvania and joined the NCI in 2007 after 18 years at the FDA. He is a member of the American Society for Clinical Investigation, received the FDA’s “Outstanding Scientist of the Year” Award, the “Outstanding Achievement Award In Biology” from the Washington Academy of Science and the Distinguished Service Medal from the PHS. He's authored over 250 peer reviewed articles and holds numerous patents concerning CpG and immunosuppressive oligonucleotides. His research focuses on the use of these oligonucleotides to improve cancer immunotherapy.

)

CBER, FDA
Bethesda, MD
USA

P. Le
Loyola University
Maywood, IL
USA

A. Ma
University of California
San Francisco, CA
USA

S. Meri (Biography
S. Meri

Seppo Meri, MD, PhD is a Professor of Immunology at the Medical Faculty, University of Helsinki, and Chief Physician of Research in Microbiology at HUSLAB, laboratory of the Helsinki University Hospital, Finland. He served as a postdoctoral fellow at the University of Texas in 1988 and in 1989-90 as an EMBO fellow at MRC, Cambridge, UK. He has published 240 original papers and 130 reviews or textbook chapters on complement, autoimmunity and microbial escape. His research interests include diseases related to disturbances in complement regulation (like hemolytic uremic syndrome), vascular damage and reasons for increased susceptibility to infections.

)

University of Helsinki
Helsinki
Finland

A Mizoguchi
Harvard Medical School
Charlestown, MA
USA

I. Muller
Imperial College London
London
UK

P Ohashi (Biography
P Ohashi

Dr. Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is the co-Director of the Campbell Family Institute for Breast Cancer Research, Senior Scientist at the Princess Margaret Cancer Centre, and Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. She is also the Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Her interests are understanding T cell tolerance, strategies to promote tissue specific immune responses and translating these findings to clinical trials.

)

Princess Margaret Cancer Centre
Toronto, Ontario
Canada

D.H. Persing
Cepheid Inc
Sunnyvale, CA
United States

J. Platt (Biography
J. Platt

Dr. Platt investigates the immunology and cell biology of transplantation. His work has included leading efforts to develop novel approaches to replacing or restoring the function of failing organs including use of genetically engineered animals as sources of cells and organs for transplantation and as incubators in which human cells might be expanded and matured. Dr. Platt’s work in transplantation immunology focuses on understanding and overcoming B cell responses to for foreign cells, tissues and organs and understanding how those responses eventuate in tissue injury. His discoveries include (i) accommodation, the acquired resistance of cells and organs to immune and inflammatory injury, (ii) the use of genetic engineering to identify and overcome barriers to xenotransplantation; (iii) the importance of endogenous agonists for inflammatory (toll-like) receptors; and (iv) the spontaneous fusion of cells as a mechanism of viral evolution and oncogenesis. Dr. Platt was educated in Medicine (USC, 1977), Pediatrics (Childrens Hospital of Los Angeles, 1980) and Nephrology, Immunology and Cell Biology (University of Minnesota, 1985). He was recipient of the Clinician-Scientist and Established Investigator awards from the American Heart Association and a MERIT award from NHLBI. He is a member of the National Academy of Medicine and the Association of American Physicians and a Fellow of the American Heart Association.

)

Mayo Clinic & Mayo Foundation
Rochester, MN
USA

D. Raoult
Unité des Rickettsies
Marseille
France

C.R Rinaldo (Biography
C.R Rinaldo

Dr. Rinaldo is Chairman and Professor of Infectious Diseases and Microbiology (IDM) in the University of Pittsburgh Graduate School of Public Health, Professor of Pathology in the University of Pittsburgh School of Medicine, and Assistant Director of Clinical Microbiology in the University of Pittsburgh Medical Center. He has been the Principal Investigator for the Multicenter AIDS Cohort Study clinical site in Pittsburgh since 1983, which investigates the natural history of HIV-1 infection in men who have sex with men. He also leads an Immunology Specialty Laboratory in the AIDS Clinical Trials Group. He has more than 360 scientific publications. He has served nationally on NIH committees and editorial boards, and was honored with a MERIT award from the NIH for support of his HIV research in 2004.

)

University of Pittsburgh - Graduate School of Public Health
Pittsburgh, PA
USA

A. Rudensky (Biography
A. Rudensky

Alexander Rudensky is Chairman of the Immunology Program and Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC), an Investigator with the Howard Hughes Medical Institute, and a Tri‐Institutional Professor at MSKCC, the Rockefeller University and Cornell University, and Professor at Gerstner School of Graduate Studies and at Weill‐Cornell Medical School. Dr. Rudensky is an internationally-recognized leader in the field of immune regulation, where he has made numerous seminal discoveries including the identification of the molecular mechanisms of regulatory T cell differentiation. Dr. Rudensky was elected to the National Academy of Sciences in 2012, the American Academy of Sciences and the National Academy of Medicine in 2015. He is the recipient of the Searle Scholar Award and more recently the Coley Award for Basic Science

)

University of Washington School of Medicine
Seattle, WA
USA

J. Schaefer
University of Texas HSC at Houston School of Dentistry
Houston, TX
USA

E. Shevach (Biography
E. Shevach

Dr. Shevach received his A.B. and M.D. degrees from Boston University. He is presently Chief, Cellular Immunology Section, Laboratory of Immunology. Dr. Shevach is the author of over 440 papers in the field of Immunology and his research interests over the years have included antigen presentation and processing, T lymphocyte activation, pathogenesis of autoimmunity, and most recently the role of regulatory T cells in immune responses. He served as Editor-in-Chief of the Journal of Immunology from 1987 to 1992 and as Editor-in-Chief of Cellular Immunology from 1996 to 2007. He is a member of the editorial boards of several journals including Immunity, Journal of Experimental Medicine, and Human Immunology.

)

NIH
Bethesda, MD
USA

J. Sprent
The Scripps Research Institute
La Jolla, CA
USA

S.-C Sun (Biography
S.-C Sun

Shao-Cong Sun received his Ph.D. degree in Microbiology from Stockholm University and pursued postdoctoral training at The Gladstone Institute of Virology and Immunology, University of California at San Francisco. He is a professor and endowed chair in Immunology at The University of Texas MD Anderson Cancer Center, where he also serves as the director of Center for Inflammation and Cancer. His major contributions include demonstration of IkBa degradation in NF-kB activation, discovery of noncanonical NF-kB pathway, and seminal findings of in vivo functions of ubiquitination in regulating T-cell activation and tolerance. He has published more than 150 scientific papers.

)

The University of Texas MD Anderson Cancer Center
Houston, TX
USA

M Taniguchi (Biography
M Taniguchi

Masaru TANIGUCHI received his M.D. and Ph.D. degrees at Chiba University School of Medicine (1974). He was appointed a Professor of Immunology at Chiba University School of Medicine (1980-2004), served as the Dean there (1996-2000) and President of the Japanese Society for Immunology (1997-1998). He was then appointed the founding Director of the RIKEN RCAI (2001-2013) and the Senior Advisor at RIKEN IMS in 2013.

He identified an NKT cell in 1986 and also an NKT cell ligand, a-galactosylceramide in 1997 and developed NKT cell-deficient mice in 1997. He was awarded the Medal with Purple Ribbon in 2004 and the Order of the Sacred Treasure in 2016 by the Emperor of Japan.

)

RIKEN Research Center. for Allergy and Immunology
Yokohama
Japan

M. Teitell
David Geffen School of Medicine at UCLA
Los Angeles, CA
USA

C Tsoukas
San Diego State University
San Diego, CA
USA

U.H Von Andrian (Biography
U.H Von Andrian

Dr. von Andrian is the Mallinckrodt Professor of Immunopathology at Harvard Medical School. Prior to joining the Faculty at Harvard Medical School in 1994, he received his M.D. and Ph.D. from the Ludwig-Maximilians University in Munich, Germany. He then completed two postdoctoral fellowships at La Jolla Institute for Experimental Medicine and UCSD and Stanford University. His scientific research is focused on the regulation and function of immune cells in health and disease. To this end, his laboratory employs intravital microscopy techniques combined with other experimental approaches to study the migration, communication, differentiation and function of immune cells in living animals.

)

Harvard University
Boston, MA
USA

G.L Waneck
Harvard Medical School,
Charlestown, MA
USA

Yuzhang Wu (Biography
Yuzhang Wu

Dr. Wu obtained M.D. in Clinical Medicine from the Secondary Military Medical University, Shanghai, and Ph.D. in Immunology from the Third Military Medical University, Chongqing, China. Currently, He is the Director of Institute of Immunology, PLA, China. He has published more than 200 SCI papers and is a named inventor of 90 issued patents.

)

Third Military Medical University
Chongqing
China

L van Kaer (Biography
L van Kaer

Luc Van Kaer received B.S., M.S., and Ph.D. degrees from Ghent University (Ghent, Belgium) and performed postdoctoral research at the Massachusetts Institute of Technology (Cambridge, MA). He subsequently joined the faculty of Vanderbilt University Medical Center (Nashville, TN), where he is currently Professor of Pathology, Microbiology and Immunology. His research program focuses on the immunological functions of innate and innate-like lymphocytes. He previously served as a Section Editor and Deputy Editor with the Journal of Immunology and he currently serves as a Consulting Editor with the Journal of Clinical Investigation. He has been on the Editorial Board of Current Immunology Reviews since 2004.

)

Vanderbilt University School of Medicine
Nashville, TN
USA

A. Adler (Biography
A. Adler

Dr. Adler received his Ph.D. in 1993 from Columbia University where he studied hormonal regulation of gene expression. His post-doctoral research at The Johns Hopkins University School of Medicine focused on studying T cell tolerance pathways, and how they impact tumor immunity. Since 1999 his laboratory at the University of Connecticut School of Medicine has continued to analyze the cellular and molecular mechanisms by which T cell tolerance to normal self and tumor antigens is programmed, and how costimulatory pathways can be engaged to elicit tumor immunity.

)

University of Connecticut School of Medicine
Farmington, CT
USA

A.F. Azad
University of Maryland
Baltimore, MD
USA

S. Bondada (Biography
S. Bondada

Dr. Subbarao Bondada is a Professor in the Department of Microbiology, Immunology and Molecular Genetics at the University of Kentucky Chandler Medical Center. He obtained his Ph. D. from the Tata Institute of Fundamental Research, Mumbai, India. He has authored more than 130 scientific publications. His research is focused on activation of normal B lymphocytes and growth regulation of malignant B cells. He is currently an Associate Editor for Frontiers in Immunology and PLOS One.

)

University Kentucky
Lexington, KY
USA

R.R. Brubaker
Michigan State University
E Lansing, MI
USA

J. Chan
Albert Einstein College
Bronx, NY
USA

A. Chopra
University Texas
Galveston, TX
USA

C.W. Cutler
Stony Brook University
Stony Brook, NY
USA

L. Denzin (Biography
L. Denzin

Dr. Denzin is an Associate Professor of Pediatrics at the, Rutgers Robert Wood Johnson Medical School and the Child Health Institute of NJ. She received a B.S. degree in Medical Microbiology from the University of Wisconsin-Madison in 1987 and a Ph.D. in Microbiology from the University of Illinois-Urbana in 1992. After 5 years of post-doctoral studies in Immunology under the tutelage of Dr. Peter Cresswell at Yale University, she was an Assistant Professor of Immunology at Duke University. In 1998 she moved her research laboratory to the Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center in Manhattan where she was an Assistant and then an Associate Member. She also held a joint appointment at the Weill Graduate School of Medical Sciences of Cornell University in Manhattan. Dr. Denzin joined the faculty of the Rutgers Robert Wood Johnson Medical School in September 2011. Her research interests include the control of immunity and autoimmunity and also in the molecular control of hematopoiesis.

)

Robert Wood Johnson Medical School
New Brunswick
USA

S. Elsawa
Northern Illinois University
DeKalb, IL
USA

K. Fujihashi (Biography
K. Fujihashi

Dr. Kohtaro Fujihashi, D.D.S., Ph.D. is a Professor, Departments Pediatric Dentistry and Microbiology, The University of Alabama at Birmingham. He has been studying T cell immunoregulatory mechanisms in the induction of secretory IgA (SIgA) immunity and oral tolerance for over two decades. During the past five years, his laboratory has extensively assessed mucosal immunity in aging. This work holds promise since nasal vaccine delivery with novel innate immune stimulants, can elicit significant immunity in the upper respiratory tract even in aging. He has published more than 200 scientific publications.

)

The University of Alabama at Birmingham
Birmingham, AL
USA

J Goverman (Biography
J Goverman

Dr. Goverman received a Bachelor’s degree in Chemistry from Brandeis University and her Ph.D. in Biological Chemistry from UCLA in 1981. Her postdoctoral fellowship at UCLA was followed by additional training at the California Institute of Technology. As a member of the Department of Molecular Biotechnology when it was founded at the University of Washington in 1992, Dr. Goverman then joined the Department of Immunology in 1994 and was appointed Chair in 2010. She has published 71 articles, is on the editorial board for Cellular Immunology and the editorial advisory board for Current Immunology Reviews published by Bentham Science Publishers.

)

University Washington
Seattle, WA
USA

G.K. Hansson (Biography
G.K. Hansson

Dr. Hansson received his MD and PhD from Gothenburg University. He is currently Professor of Cardiovascular Research at Karolinska Institute and affiliated with its Department of Medicine and the Center for Molecular Medicine. Dr Hansson´s research deals with mechanisms of atherosclerosis, the disease that causes myocardial infarction and stroke. He has discovered that inflammation plays a major role in atherosclerosis, and is currently working on prevention and treatment of cardiovascular disease.

Dr Hansson is the Secretary General of the Royal Swedish Academy of Sciences, Vice Chairman of the Board of Directors of the Nobel Foundation and a member of the Nobel Assembly at Karolinska Institute. He is also a member of Academia Europaea and has received several awards for his contributions to medicine.

)

Center for Molecular Medicine
Karolinska Institute, Stockholm
Sweden

A Houghton
Cornell University
New York, NY
USA

H.-M. Jack
University of Erlangen
Erlangen
Germany

H Kikutani
Osaka University
Osaka
Japan

P Kropf (Biography
P Kropf

Pascale Kropf did her PhD at Imperial College London on T helper cell responses in experimental leishmaniasis. She is a senior lecturer in Immunology at Imperial College London. The main focus of her work is dissecting the immunological mechanisms responsible for nonhealing human cutaneous and visceral leishmaniasis in Ethiopia.

)

Imperial College London
London
UK

Gregory B. Lesinski (Biography
Gregory B. Lesinski

Gregory B. Lesinski, PhD, MPH, is Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Dr. Lesinski's research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are modulation of cytokines and downstream signaling pathways to maximize the effect of immune based therapy.

)

Winship Cancer Institute of Emory University
Atlanta
Georgia

B Malissen
Centre d'Immunology Marseille-Luminy
INSERM, Marseille
France

T Meyer
Max Planck Institute for Infection Biology
Berlin
Germany

H. Moll (Biography
H. Moll

Heidrun Moll performed her doctoral studies at the Max Planck Institute of Immunobiology, Freiburg, and her post-doctoral training was at WEHI in Melbourne. She was assistant professor at the University of Erlangen Medical School and moved to the then newly established Research Center for Infectious Diseases, Würzburg. Since 1995, she is professor at the University of Würzburg Medical School, and head of the Infection Immunology Unit. Furthermore, she is member of the Scientific Advisory Council of the Robert Koch Foundation. Her scientific achievements were honored with the Siebold Nagasaki Medical Award, and in 2016, with the Rudolf-Leuckart Award.

)

University of Wuerzburg
Wuerzburg
Germany

S. Nagata
Immunology Frontier Research Center (IFReC)
Osaka University
Osaka
Japan

T.H. Ottenhoff
Leiden University
Leiden
The Netherlands

R. Phipps (Biography
R. Phipps

Dr. R. P. Phipps earned his B.S.M.T. in medical technology and graduated magna cum laude at Loyola College, Baltimore, Maryland. Upon completion of his doctorate degree in Microbiology/Immunology, from the Medical College of Virginia, he held postdoctoral fellowships at the Medical College of Virginia and Duke University. In 1983 Dr. Phipps joined the faculty at the University of Rochester.

Dr. Phipps has been awarded six patents; 4 on bacterial auto inducer molecules, 1 on platelet production and 1 on methods to treat thyroid eye disease. Dr. Phipps has received numerous awards and honors including the Arthur Kornberg Research Award, Burroughs-Wellcome Foundation Faculty Scholar, and the University of Rochester Pre and Postdoctoral Student Mentoring Award. Dr. Phipps has dedicated his career to advancing biomedical research.

)

University Rochester School Medicine & Dentistry
Rochester, NY
USA

H. Rammensee
University Tubingen
Tubingen
Germany

A. Rasley (Biography
A. Rasley

Dr. Rasley obtained a doctorate (Ph.D.) in Immunology from the University of North Carolina at Charlotte where she studied innate immune responses in the central nervous system. She is currently a Senior Staff Scientist at Lawrence Livermore National Laboratory (LLNL) where much of her research has focused on host-pathogen interactions and nanoparticle mediated immune modulation strategies for infectious diseases. Dr. Rasley is also part of the management team at LLNL overseeing work with pathogens that require advanced biosafety containment.

)

Lawrence Livermore National Laboratory
Livermore, CA
USA

S. Romagnani
University Florence
Florence
Italy

D. Sacks
Laboratory of Parasitic Diseases, NIAID
Bethesda, MD
USA

R. Schell
University Wisconsin
Madison, WI
USA

S. Singh (Biography
S. Singh

Am presently the Chair, Department of Pediatrics and heading the Pediatric Allergy and Immunology Unit at the Advanced Pediatrics Center in PGI, Chandigarh, India. Am also the Principal Investigator for Centre for Advanced Research in Primary Immunodeficiency Diseases, Indian Council of Medical Research, PGI Chandigarh. Awarded James Flett Endowment Prize and Gold Medal (1985) by Indian Academy of Pediatrics; Zydus Oration (2003) and IRA Oration (2010) by Indian Rheumatology Association; Von Pirquet Oration (2003) and V. Raju Gold Medal (2004) by Indian College of Allergy and Applied Immunology; Chaturvedi Kalawati Jagmohan Das Memorial Awards (2009 and 2011) by Indian Council of Medical Research.

)

Post Graduate Institute of Medical Education and Research
Chandigarh
India

P. Srivastava (Biography
P. Srivastava

Research interests: Our laboratory’s research interests lie in antigen presentation by MHC molecules, and immune response to cancer. Our laboratory has developed innovative approaches for therapy of cancer, infections and autoimmune disorders. It is our view that the HSP-peptide interaction is an evolutionary precursor to the MHC-peptide interaction and lies at the center of a wide array of immunological phenomena. More recently, we have been involved in genomic analysis of tumors as a tool to define the “immunomes” of mouse and human cancers.

Clinical interests: Personalized, individual-specific genomics-driven Immunotherapy of epithelial ovarian cancers.

)

University Connecticut
Farmington, CT
USA

S. Swain
Trudeau Institute Inc.,
Saranac Lake, NY
USA

D. Taub
National Institute of Health
Baltimore, MD
USA

G. Tsokos
Walter Reed Army Institute
Silver Spring, MD
USA

A. Vallejo
Hospital Virgen Rocio
Seville
Spain

M.G. Von Herrath
La Jolla Institute Allergy & Immunology
San Diego, CA
USA

H Wekerle
Max Planck Institute Neurobiology
Klopferspitz
Germany

K. Wucherpfennig
Dana Farber Cancer Institute
Boston, MA
USA

C. Akin
Brigham and Women’s Hospital
Boston, MA
USA

J. Bach
Hopital Necker
Paris
France

P.N. Boyaka
The Ohio State University
Columbus, OH
USA

R. Buckley
Duke University
Durham, NC
USA

T.C Chiles
Boston College
Chestnut Hill, MA
USA

P. Cohen
University of Pennsylvania School of Medicine
Philadelphia, PA
USA

G. Deniz (Biography
G. Deniz

Dr. Gunnur Deniz is a Professor of Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul. She is graduated from Istanbul University, Faculty of Sciences, Department of Biology in 1985 and received her M.Sc. degree in Physiology in 1989. Between 1990-1994 she was granted by the Turkish Republic Higher Education Council (YÖK) with a PhD fellowship to study at the Department of Immunology, University of Liverpool and received her PhD degree in immunology in 1994. She is the chairman of the Immunology Department at DETAE since 2002, and has also been working as a Vice President of DETAE since 2005. Since 2006 she is the President of the Turkish Society of Immunology. Most of her work is focused on functional and phenotypical characterization of NK cells, primary immunodeficiencies, allergy and immunohematology.

)

Institute of Experimental Medicine
Istanbul University, Istanbul
Turkey

B Diamond (Biography
B Diamond

Betty Diamond received her MD from Harvard Medical School and performed a residency in Internal Medicine at Columbia Presbyterian Medical Center. She received her rheumatology training at the Albert Einstein College of Medicine. She has been Chief of Rheumatology at Albert Einstein and Columbia University and is currently Head of the Center of Autoimmune and Musculoskeletal Diseases at the Feinstein Institute for Medical Research.

Her research has focused on the induction and pathogenicity of autoantibodies in SLE. Most recently, she has become interested in the anti-inflammatory effects of C1q. In recent years, she has also become involved in clinical trials in SLE and has led several clinical trials of novel therapeutics.

She has served on several committees of the American College of Rheumatology (ACR) and has served on the Board of Directors as well. She has received the Outstanding Investigator and the Mentoring award of ACR. She is a member of the National Academy of Medicine and past president of the American Association of Immunologists.

)

The Feinstein Institute Medical Research
Manhasset, NY
USA

P. Ferrier
Aix-Marseille University UM2
Marseille
France

N. Glaichenhaus
Université de Nice-Sophia Antipolis
Valbonne
France

R.L. Guerrant
University Virginia
Charlottesville, VA
USA

W.R. Heath (Biography
W.R. Heath

Professor William Heath obtained a Ph.D. in Immunology from the University of Melbourne, Australia. Currently, he is a Professor and an NHMRC Senior Principal Research Fellow at the Department of Microbiology and Immunology, within the Peter Doherty Institute of Infection and Immunity at the University of Melbourne. He has published over 220 papers, with a total of more than 20,000 citations and was made a Fellow of the Australian Academy of Science in 2008.

)

The University of Melbourne
Parkville, VIC
Australia

C. Hunter
University Pennsylvania
Philadelphia, PA
USA

S Jonjic
University of Rijeka
Rijeka
Croatia

J.R. Klein
University of Texas HSC - Houston
Houston, TX
USA

V.K. Kuchroo (Biography
V.K. Kuchroo

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston, an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is also the Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases - particularly the role of co-stimulation - the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction.

)

Brigham and Women´s Hospital
Boston, MA
USA

M. Lopes-Virella
Medical University of South Carolina
Charleston, SC
USA

C. Melief (Biography
C. Melief

Cornelis (Kees) JM Melief is emeritus professor at Leiden University and Chief Scientific Officer (CSO) of ISA Pharmaceuticals. He has made many contributions to basic immunology and experimental and clinical tumor immunology. Recently effective immunotherapy of tumors with synthetic long peptides (SLP) was developed in mouse and rabbit models. This has led to the implementation of clinical trials in patients with cancer of viral and non-viral origin. Recently clinical effectiveness was shown in the treatment of patients with established lesions caused by high risk human papilloma virus type 16 (HPV 16).

)

Leiden University
Leiden
The Netherlands

J. Mizgerd
Harvard School of Public Health
Boston, MA
USA

M Moser
Graz University
Graz
Austria

Pearay L. Ogra
State University of New York
Children's Hospital of Buffalo
Buffalo
New York

A. Perl (Biography
A. Perl

Andras Perl received his MD and PhD from Semmelweis University in Budapest, Hungary. He was trained in Internal Medicine at Semmelweis and Rheumatology/Immunology at the University of Rochester. He held faculty positions at Semmelweis, the University of Rochester, Roswell Park Memorial Institute, and the State University of New York (SUNY). He has been Professor of Medicine, Microbiology and Immunology since 1997, Chief of Rheumatology since 2001 at SUNY. His team has identified disease susceptibility genes that regulate mitochondrial homeostasis and cell death signal processing in mouse models and patients with autoimmunity, cancer, metabolic diseases, which led to successful clinical trials.

)

SUNY Syracuse College Medicine
Syracuse, NY
USA

C.D. Platsoucas
Old Dominion University
Norfolk, CA
USA

R.M Ransohoff
Lerner Res. Institute Cleveland Clinic Foundation
OH
USA

P. Ricciardi-Castagnoli
University Milano Bicocca
Milan
Italy

P.J Rossman
University Pennsylvania
Philadelphia, PA
USA

M. Sandor
University Wisconsin
Madison, WI
USA

W Schwaeble
University of Leicester,
Leicester
UK

S Sozzani
University of Brescia
Milan
Italy

B.E Strober
New York University School of Medicine
New York, NY
USA

K Takatsu
University Tokyo
Tokyo
Japan

A.W. Taylor-Robinson (Biography
A.W. Taylor-Robinson

Dr Taylor-Robinson received a BSc in medical microbiology (immunology major) from University College London and a PhD in parasite immunology from the University of Glasgow for work on cellular immunity to malaria. He has 30 years’ research experience of infectious disease immunology, with a focus on malaria, dengue and other mosquito-borne diseases, now covering Zika. He is currently Professor of Immunology & Haematology at Central Queensland University where he investigates pathogens affecting human wellbeing in rural Australia. He has authored over 150 peer-reviewed journal.

)

Central Queensland University
Brisbane
Australia

M. Tsokos
Institute of Legal Medicine and Forensic Sciences, Charite - University Medicine
Berlin
Germany

E. Vivier (Biography
E. Vivier

Eric Vivier, DVM, PhD, is a professor of immunology at Aix-Marseille University and Assistance Publique - Hôpitaux de Marseille. He graduated from the Ecole Nationale Vétérinaire de Maisons-Alfort and received his doctoral degree in immunology from Paris XI University. He performed his postdoctoral training at Harvard Medical School (Dana-Farber Cancer Institute). In 1993, he joined the Centre d'Immunologie de Marseille-Luminy (CIML) and became its director in 2008. His research is focused on Innate Lymphoid cells (http://www.ciml.univ-mrs.fr/science/lab-eric-vivier/home>), and he has authored more than 300 publications (http://scholar.google.fr/citations?user=NlmFOgMAAAAJ&hl=fr&oi=ao>). In 1999, Eric Vivier cofounded the biotech company Innate-Pharma (http://www.innate-pharma.com>). In 2014, he cofounded the immunology cluster, Marseille-Immunopole (http://marseille-immunopole.org>).

)

University Mediterranee
Marseille
France

M. Vordermeier (Biography
M. Vordermeier

I am cellular immunologist working on human and bovine tuberculosis for more than 25 years. My group has been for engaged in studying the immune responses in cattle after Mycobacterium bovis infection, and after vaccination against bovine tuberculosis. In particular we are applying this knowledge to development of improved TB cattle vaccines and immunodiagnostic reagents including reagents that are compatible with vaccination (DIVA). We are particularly interested in defining host markers that correlate either with disease severity or with vaccine efficacy.

)

TB Research Group
Surrey
UK

T. Whiteside (Biography
T. Whiteside

Dr. Theresa Whiteside is a Professor of Pathology, Otolaryngology and Immunology at the University of Pittsburgh and member of the University of Pittsburgh Cancer Institute. She is a recognized expert in immune monitoring of patients with cancer and has authored over 575 peer-reviewed publications and 127 chapters as well as a book on human tumor-infiltrating lymphocytes, also co-editing several scientific books. She has trained 94 post-doctoral fellows from the United States and abroad.

Her research interests include tumor immunology and immunotherapy. Currently, she is investigating the role of regulatory T cells in cancer progression as well as contributions of tumor-derived exosomes (TEX) to dysfunction of CD8+ effector cells in the peripheral circulation of patients with cancer and in the tumor microenvironment.

)

University Pittsburgh Canc. Institute
Pittsburgh, PA
USA

S.S. Zamvil
University of California at San Francisco
San Francisco, CA
USA












Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science